On February 26, 2018, AMCP joined 11 organizations in letter to the OIG in support of establishing a safe harbor provision that would encourage the development of additional value-based contracts for the Medicare and Medicaid populations.
Press Release: Academy of Managed Care Pharmacy (AMCP) CEO Susan A. Cantrell, RPh, CAE, issued the following statement on President Trump’s budget proposal for fiscal year 2019.
AMCP CEO Blog: The FDA approved 46 novel drugs in 2017, a 21-year high. However, it could take as long as six months for some of these groundbreaking medicines to reach patients.
On February 1, 2018, CMS released its 2019 Draft Call Letter. AMCP prepared in initial summary of the highlights contained in the Draft Call Letter. Of particular interest to AMCP members, CMS proposed new strategies for identifying potential opioid abuse which will work with the proposed codification of the current Opioid Monitoring System (OMS) under the Comprehensive Addiction and Recovery Act of 2015 (CARA).
On January 30, 2018, AMCP delivered remarks to the FDA at an opioid policy steering committee meeting. AMCP commended the FDA for establishing the OPSC and for seeking public input to help identify key areas of focus that the FDA can address. AMCP focused on the following three areas; REMS; Labeling, Packaging, Storage, and Disposal; and Additional Focus Areas where AMCP feels that the FDA can be actively involved in combating the opioid epidemic.